SHOT.NASDAQSafety Shot, INC
10-Q: Safety Shot Inc. Reports First Quarter 2024 Results, Revenue Growth Offset by Increased Operating Expenses
Sentiment:
Quarterly Report
Safety Shot Inc. reported a significant increase in revenue for the first quarter of 2024, driven by the launch of its Safety Shot product, but also experienced a substantial net loss due to increased operating expenses and a one-time inventory write-off.
Capital raiseThe company's low cash position and working capital, combined with significant net losses, suggest a potential need for additional capital raising.The company issued 2,369,668 shares at market price in a private placement for $5,000,000 subsequent to March 31, 2024.
Worse than expectedThe company's net loss of $15,674,671 was significantly worse than the $1,308,174 loss in the same period last year.The company's operating expenses increased dramatically to $12,956,552, compared to $1,244,953 in the prior year.The company's auditors have raised substantial doubt about its ability to continue as a going concern.
Summary
- Safety Shot Inc. reported its financial results for the first quarter of 2024, showing a revenue of $170,732, a significant increase compared to $34,788 in the same period of 2023.
- The company's cost of sales was $2,383,285, which included a one-time inventory write-off of $1,744,714 due to rebranding issues.
- Operating expenses totaled $12,956,552, primarily due to marketing, research and development, legal and professional fees, and stock-based compensation.
- The company experienced a net loss of $15,674,671, or $0.33 per share, compared to a net loss of $1,308,174, or $0.05 per share, in the first quarter of 2023.
- As of March 31, 2024, the company had cash and cash equivalents of $2,046,355 and a working capital of $947,504.
- The company's auditors have raised substantial doubt about its ability to continue as a going concern due to accumulated deficits and cash flow used in operations.
Sentiment
Score: 3
Explanation: The document presents a mixed picture with strong revenue growth offset by significant losses, high operating expenses, and going concern doubts. The numerous legal proceedings and the need for potential capital raising further contribute to a negative sentiment.
Positives
- The company successfully launched its Safety Shot product in December 2023, leading to a significant increase in revenue.
- The company is actively pursuing a future product line, including a powdered stick pack version of Safety Shot.
- The company is in discussions with Big Box stores for a potential launch in the early second quarter of 2024.
- The company has a diverse product pipeline including treatments for hair loss, vitiligo, and sexual wellness.
Negatives
- The company experienced a substantial net loss of $15,674,671 in Q1 2024.
- Operating expenses significantly increased to $12,956,552.
- A one-time inventory write-off of $1,744,714 was recorded due to rebranding issues.
- The company's auditors have raised substantial doubt about its ability to continue as a going concern.
- The company has a working capital of only $947,504 as of March 31, 2024.
Risks
- The company's ability to continue as a going concern is in doubt due to accumulated deficits and cash flow used in operations.
- The company is subject to various legal proceedings and claims, which could have a material adverse effect on its financial position.
- The company's success depends on the commercialization of the Safety Shot Dietary Supplement, which is subject to regulatory risks.
- The company faces competition from other companies in the health and wellness market.
- The company's reliance on contract manufacturers and third-party warehouses exposes it to supply chain risks.
Future Outlook
The company intends to continue its current product lines, except for its products which contain CBD, and will focus its efforts on the commercialization of the Safety Shot Dietary Supplement. The company is also advancing several formulations to address other health conditions and plans to complete the formulation and test launch of a women's sexual wellness product in Q4 2024.
Management Comments
- The company is committed to driving continuous improvement through innovation.
- The company believes that the Safety Shot Dietary Supplement stands as a unique product in the liquid dietary supplement market.
- The company is focused on the commercialization of a 12-ounce product positioned as a dietary supplement.
- The company is actively pursuing a future product line, including a convenient powdered stick pack version.
Industry Context
The company operates in the competitive health and wellness market, which includes numerous companies involved in the production of health and welfare products. The company's focus on the Safety Shot Dietary Supplement positions it in the growing market for dietary supplements aimed at reducing the effects of alcohol consumption. The company's product pipeline also includes treatments for other health conditions, aligning with broader trends in the health and wellness industry.
Comparison to Industry Standards
- The company's revenue of $170,732 for the quarter is relatively low compared to established companies in the dietary supplement industry, which often report revenues in the millions or tens of millions.
- The company's significant net loss of $15,674,671 is concerning and indicates that the company is not yet profitable, which is not uncommon for early-stage companies in the health and wellness sector.
- The company's high operating expenses, particularly in marketing and stock-based compensation, are typical for companies in the growth phase, but need to be managed carefully to achieve profitability.
- The company's cash position of $2,046,355 is relatively low and may require additional capital raising to support its operations and growth plans.
- The company's auditors' concerns about its ability to continue as a going concern are a significant red flag and highlight the financial challenges the company is facing.
- Compared to other companies in the dietary supplement space, Safety Shot is still in the early stages of commercialization and needs to demonstrate its ability to scale production, distribution, and sales to achieve sustainable growth.
Legal Proceedings
- Intracoastal Capital, LLC filed a lawsuit against the company alleging breach of a common stock warrant.
- The company filed a lawsuit against Capybara Research, Igor Appelboom, and Accretive Capital LLC d/b/a Benzinga for securities fraud and tortious interference.
- Sabby Volatility Warrant Master Fund Ltd. filed two lawsuits against the company related to a delayed spin-off and a warrant exercise.
- 3i LP filed a lawsuit against the company for alleged denial of a warrant exercise.
- Coachella Music Festival, LLC filed a lawsuit against the company for trademark infringement, which was later settled.
- Bigger Capital fund, L.P. filed a lawsuit against the company related to a warrant to purchase shares.
- Alta Partners, LLC filed a lawsuit against the company related to a warrant to purchase shares.
Stakeholder Impact
- Shareholders are negatively impacted by the significant net loss and the going concern doubts.
- Employees may be concerned about the company's financial stability and future prospects.
- Customers may be affected by potential changes in product availability or quality due to financial constraints.
- Suppliers and creditors may face increased risks due to the company's financial challenges.
Next Steps
- The company intends to continue its current product lines, except for its products which contain CBD.
- The company will focus its efforts on the commercialization of the Safety Shot Dietary Supplement.
- The company is advancing several formulations to address other health conditions.
- The company plans to complete the formulation and test launch of a women's sexual wellness product in Q4 2024.
- The company is in discussions with Big Box stores for a potential launch in the early second quarter of 2024.
Key Dates
| Date | Description |
|---|---|
| 2016-02-29 | This date is mentioned in the document but has no specific context. |
| 2020-01-01 | Start date of the Economic Injury Disaster Loan Program. |
| 2021-01-01 | Start date of the Economic Injury Disaster Loan Program. |
| 2021-07-01 | Effective date of the office lease. |
| 2021-12-31 | End date of the Economic Injury Disaster Loan Program. |
| 2022-01-01 | Start date of the Economic Injury Disaster Loan Program. |
| 2022-04-19 | Date of Convertible Promissory Notes. |
| 2022-04-20 | Date of Convertible Promissory Notes. |
| 2022-12-31 | End date of the Economic Injury Disaster Loan Program. |
| 2023-01-01 | Start date of various agreements and programs. |
| 2023-01-18 | Date of PIPE Agreement. |
| 2023-01-19 | Date of PIPE Agreement. |
| 2023-01-22 | Date of RD Agreement. |
| 2023-01-23 | Date of RD Agreement. |
| 2023-06-27 | Date of Chijet stock receipt. |
| 2023-07-01 | Start date of Asset Purchase Agreement. |
| 2023-07-09 | Date mentioned in relation to convertible notes. |
| 2023-07-10 | Date of Asset Purchase Agreement with GBB Drink Lab, Inc. |
| 2023-08-01 | Start date of Private Investment in Public Equity and IPO. |
| 2023-08-31 | End date of Private Investment in Public Equity and IPO. |
| 2023-09-05 | Date of Sabby Volatility Warrant Master Fund Ltd. lawsuit. |
| 2023-11-30 | Date of Intracoastal Capital, LLC lawsuit. |
| 2023-12-01 | Start date of Restricted Common Stock. |
| 2023-12-31 | End date of various agreements and programs. |
| 2024-01-01 | Start date of various agreements and programs. |
| 2024-01-10 | Date of Bigger Capital fund, L.P. lawsuit. |
| 2024-01-16 | Date of 3i LP lawsuit. |
| 2024-01-18 | Date of Alta Partners, LLC lawsuit. |
| 2024-01-19 | Date of Coachella Music Festival, LLC lawsuit. |
| 2024-02-09 | Date of Sabby Volatility Warrant Master Find Ltd. lawsuit. |
| 2024-03-31 | End of the reporting period. |
| 2024-04-01 | Date mentioned in relation to a financial metric. |
| 2024-05-10 | Date of share count. |
| 2024-05-14 | Date mentioned in relation to a financial metric. |
| 2024-05-15 | Date of report. |
Keywords
Safety Shot, dietary supplement, blood alcohol reduction, revenue, net loss, operating expenses, going concern, intellectual property, warrants, convertible notes
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.